DAX®13.787,73-1,44%TecDAX®3.262,41-0,90%Dow Jones 3030.814,26-0,57%Nasdaq 10012.803,93-0,73%

PRESS RELEASE: Formycon's Scientific Collaboration Partners present FYB207 Results at International Keystone Symposium

| Quelle: Dow Jones Newsw... | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-News: Formycon AG / Key word(s): Scientific publication/Miscellaneous
Formycon's Scientific Collaboration Partners present FYB207 Results at International Keystone Symposium
2021-01-13 / 07:30
The issuer is solely responsible for the content of this announcement.
Press Release // January 13, 2021
Formycon's Scientific Collaboration Partners present FYB207 Results at International Keystone Symposium
Munich - Formycon (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that its academic partners of the Technical
University of Munich, present results on Formycon's COVID-19 drug (FYB207).
The results of the publication (BioRxiv Preprint: https://doi.org/10.1101/2020.12.06.413443) were approved for an
E-Poster presentation at the international "Keystone Symposia - Antibodies and Vaccines as Drugs for COVID-19" on
today's date titled "Highly efficient inhibition of SARS-CoV-2 entry by a biologically unique ACE2-IgG4-Fc fusion
protein with a stabilized hinge region." The poster will be available soon on our website: https://www.formycon.com/en/
Formycon's innovative SARS-CoV-2-Blocker completely prevents in-vitro infection of cells. Compared to vaccines and
therapeutic antibodies, the ACE2-IgG4-Fc fusion protein is maximally protected against virus escape by mutation. The
risk of infection enhancement by vaccines and IgG1 antibodies described for corona viruses is minimized by using the
IgG4 portion in the fusion. FYB207 also has inherent enzymatic activity that may provide additional protection for the
lungs and cardiovascular system in symptomatic patients. In addition, FYB207 can potentially be used for treatment of
all corona viruses that use ACE2 as an entry portal.
Formycon is currently preparing documents for a Scientific Advice at the Paul-Ehrlich-Institute on the preclinical and
clinical studies for FYB207, which is planned to be conducted within the next weeks. The clinical trial is expected to
start during the second half of 2021.
About Formycon:
Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The
company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value
chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing
approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible
with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its
extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of
antibody-based COVID-19 compounds.
Sabrina Müller
Senior Manager Corporate Communications and Investor Relations
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
Phone: +49 (0) 89 - 86 46 67 149
Fax + 49 (0) 89 - 86 46 67 110
Sabrina.Mueller@formycon.com // www.formycon.com
This press release may contain forward-looking statements and information which are based on our current expectations
and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, performance of the company, development of the
products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the
research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other
governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent
litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does
not provide any representation, warranties or any other guarantees that the products will receive the necessary
regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no
obligation to update these forward-looking statements or to correct them in case of developments which differ from
those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or
subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public
offering intended. This document and the information contained therein may not be distributed in or into the United
States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would
be prohibited. This document does not constitute an offer for the sale of securities in the United States.
2021-01-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Phone: 089 864667 100
Fax: 089 864667 110
Internet: www.formycon.com
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart,
Tradegate Exchange
EQS News ID: 1160232

End of News DGAP News Service

(MORE TO FOLLOW) Dow Jones Newswires

January 13, 2021 01:30 ET ( 06:30 GMT)

Das könnte Sie auch interessieren



Aktuelle Videos

HSBC Trading TV



Börsen & Märkte


zur Mediathek

Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 03 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen